All News

DMARDs,biologics,RA

Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs

d Jack Cush, MD

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Read Article
ANA.Wikipedia.jpg (keep)

Best of 2023: New Laboratory Insights for the ANA+ Consult

d Jack Cush, MD

A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).

Read Article
CPPDwrist.JPG

Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease

d Jack Cush, MD

The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.

Read Article
Balance Empathy Emotional Heart

Best of 2023: How Being a Patient Taught Me to Be a Better Doctor

d Marcela Ferrada, MD

When I was accepted into medical school, my Dad (a trauma surgeon) taught me that as a doctor I should not judge and do my best not to let my personal views interfere with how I manage and interact with my patients.

Read Article
Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/HpOdaXAxff https://t.co/HpOdaXAxff https://t.co/IrjJcxUG9b

Links:

Dr. John Cush RheumNow ( View Tweet)
MSK Syndrome from Dupilimab, an IL-4/13 Inhibitor. A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/w5djtUzAGG https://t.co/eGMJQJ6Pw2

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study.of 370 #FM pts (79% F; age 34yrs), and 79% were female w/ 14.3 tender points. A delay in Dx was signif correlated with Sx Severity Scale (r = 0.14) & tender points (r = 0.16), but not widespread pain. Early Dx = less severe FM. https://t.co/URvzRa1c3P

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/bLFmRdulCw

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies, 4661 pts. Corticosteroids reduced mortality in more severe CAP(RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/1QbuCZRXze https://t.co/16qiqIatJq

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK

Links:

Dr. John Cush RheumNow ( View Tweet)

Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/vZALPMU8lI https://t.co/yGvDLHIp5y

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is just about a month away--will we see you there? You can attend virtually or in-person at our Dallas, TX location. With over 20 dynamic speakers, we are confident you'll leave feeling inspired! https://t.co/y6BVvZDcku https://t.co/NqzkVd3l8p

Links:

Dr. John Cush RheumNow ( View Tweet)
How Being a Patient Taught Me to Be a Better Doctor” Dr. Marcella Ferrada (@maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician. https://t.co/BZPlLzdSsk https://t.co/Ykh6AhAnxn

Links:

Dr. John Cush RheumNow ( View Tweet)
Browse through this update to learn more about the real impact of comorbidities on patients living with SpA. Sponsored by Novartis Medical Affairs. https://t.co/0BCVvTYzAl https://t.co/2RhJomr6Dr

Links:

Dr. John Cush RheumNow ( View Tweet)
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/eUu23a2QDn https://t.co/RHDLTm9NMD

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family? Click here to answer >> https://t.co/IagcDC24rZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2023 - Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/Uh2RFrfpc2

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM Case: 44 yoF w/ 1wk hx of pustular rash, 1st on face, then legs. Also has ankle pain &; odynophagia. PMHx oral ulcers. Exam: Aphthous ulcers & all labs were negative (ANA, ANCA, HIV, RPR, etc). Skin Bx= small-vessel vasculitis. What Dx? https://t.co/IcIQwP9z7C

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×